WAYS OF LIFE QUALITY IMPROVEMENT OF THE PATIENTS WITH NON-SMALL-CELL CANCER OF LUNG WITH BRAIN METASTASES
Abstract
The analysis of the results of combined usage of temodal and radiotherapy among 37 patients with non-small-cell lung cancer (NSCLC) IIIA, IIIB stages with brain metastases was held. The comparative analysis of two groups was held: the 1st group – 27 patients with NSCLC, administered radiotherapy according to the above mentioned scheme with lomustine chemo modification, 40 mg per week (TFD 120-160 mg); the 2nd group – 30 patients with NSCLC, administered radiotherapy according to the same scheme without any modification. During the process of therapy one could observe improvement of neurological state of majority of patients in main group and control groups 1 and 2 (85.3%, 86.9%, 88.8%), respectively. Total survival rate of patients in main group was 16%, and median was 8 months, while in the 1st group this parameter was 5.5%, median was 6.2 months, respectively, Р<0.05. In the 2nd group no patient survived one-year term and median was 4 months. Following the treatment one could admit that combined usage of temodal and radiotherapy improves direct results, median and one-year survival rate among the patients of this category, saving the quality of their life according to the analysis data of hematological and non-hematological reactions.
Downloads
References
2. Эффективность лечения одиночних метастазов в головном мозге взависимости от груп прогноза / З.П. Михина, С.И. Ткачев, О.П. Трохимова [та ін.] // Вопр. онкол. –2009. –Т. 55, № 2. – С. 205-209.
3. Recursive partitioning analysis classifications I and II: applicability evaluated in a randomaized trial for resected single brain metastases / W.F. Regine, A. Rogozinska, R.J. Kryscio [et al.] // Amer. J. Clin Oncol-2004. –Vol. 27. – P. 505-509.
4. RPA classifiscation has prognostic significance for surgically resected single brain metastasis / R.D. Tendulkar, S.W. Liu, G.H. Barnett [et al.] // Int. J. Radias. Oncol. Biol. Phys. – 2006. – Vol. 66. – P.810-817.
5. Temozolomide for the treatment of recurrent supratentorial glioma results of a compassionate use program in Belgium / E. Everaet, B. Neyns, E. Joosens [et al.] // J Neurooncol.– 2004.– № 70. – P. 37-48.
6. Phase II trial of lomustine plus temozolomide chemotherapy im addition to radiotherapy in newly diagnosed glioblastoma: UKT-03 / U. Herrlinger, J. Rieger, D. Koch [et. al.] // J Clin Oncol. – 2006. – Vol. 24. – P. 4412-4417.
7. Temozolomide 3 weeks on and 1 week of as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia(GICNO) / A. Brandes, A. Tosoni, G. Cavallo [et. al.] // Br J Cancer. – 2006. – Vol. 95-P. 1155-60
8. Is protracted low-dose temozolomide feasible in glioma patients? / A.Tosoni, G. Cavallo, M. Ermani [et. al.] // Neurology. – 2006. – Vol. 66. – P. 427-429.
9. Chemoradiotherapy in malignant glioma: standard of care and future directions / R. Stup, M.E. Hegi, M.R. Gilbert [et. al.] // J Clin Oncol. – 2007. – Vol. 25. – Р. 4127-4136.
10. Жукова Л.Г. Оценка непосредственной эффективности противоопухолевой терапии / Л.Г. Жукова // Вместе против рака. – 2007. – C. 1-2:33-35.
The Journal of V. N. Karazin Kharkiv National University, series Medicine has following copyright terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
